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In clinical practice and screening programs, variations between one equation and 
another, specifically in early stages of CKD, should be considered.
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Objectives: Exploratory studies suggest that mineralocorticoid-receptor antago-
nists (MRAs) may improve outcomes in patients with diabetic kidney disease (DKD). 
Finerenone (BAY 94-8862) is a selective, potent and non-steroidal MRA for the treat-
ment of patients with DKD, currently studied in two clinical phase III trials. Early 
modeling investigated the implications of using finerenone in addition to standard 
of care. MethOds: A Markov cohort model was used to emulate disease history, 
treatment effects, and outcomes for DKD patients with various disease severi-
ties (by albuminuria, measured by urinary-albumin-creatinine ratio [UACR], and 
chronic kidney disease [CKD] stage, measured by estimated glomerular filtration 
rate [eGFR]). Efficacy of finerenone is accomplished by reducing UACR, evidenced by 
phase 2 trial data. The model has UK settings; inputs are from NHANES 1999-2008, 
adapted to UK population, USRDS 2009, various registries, and trials. Sensitivity 
analyses explored which patient subpopulation would benefit to what extent from 
finerenone treatment. Results: The model predicts that finerenone is an effective 
treatment option for DKD patients, primarily by virtue of reduced risk of end-stage 
renal disease (ESRD) and renal death (absolute risk reductions [ARR] of up to 8.3% 
and 8.2%, respectively, for advanced DKD, i.e. macro-albuminuria and CKD3/4) and 
increased health-related quality of life, and that it would generate cost savings on 
renal replacement therapy (up to £5,353 for advanced DKD). From a clinical out-
comes perspective the optimal time point to begin finerenone treatment appears 
to be after patients have progressed to either macro-albuminuria or CKD stage 3, as 
represented by both phase III trial populations. Reduced CV events and CV mortality, 
however, are greatest (ARR of up to 3.7% and 4.7%, respectively) when finerenone 
treatment is started in CKD stages 3 or earlier. cOnclusiOns: Treatment with the 
MRA finerenone appears to be of significant benefit to patients and the healthcare 
system, particularly if initiated in advanced stages of DKD.
PUK4
data Mining Based on real World data in ChroniC Kidney disease 
Patients not on dialysis: the Key role of early heMogloBin levels 
Control
Frimat L1, Pau D2, Sinnasse-Raymond G2, Choukroun G3
1INSERM CIC-EC CIE6, Vandoeuvre, France, 2Roche, Boulogne-Billancourt, France, 3CHU Amiens, 
Amiens, France
Objectives: The aim of the OCEANE non interventional study was to describe in real 
life conditions the management of anaemia with C.E.R.A. in patients with chronic 
kidney disease not on dialysis. We used data from this study to perform exploratory 
analysis to evaluate factors influencing haemoglobin levels. MethOds: To iden-
tify these factors, supervised and unsupervised data mining models and statisti-
cal approaches such as Random forest, hypercube analysis, Bayesian networks and 
mixed model for repeated measures were used. For supervised analysis, the targeted 
outcome measure was the haemoglobin level around 6 month of treatment, using 
EMA guidelines (haemoglobin level between [10-12] g/dL). As treatment patterns are 
very different, analyses have been performed by subgroup of patient naïve or not of 
ESA. Patients were followed up every 3 months during 1 year. Results: 616 adult 
patients were included/followed in the OCEANE study between 2009 and 2011, 609 
patients were taken into account for these analyses (haemoglobin available at base-
line) and 44% were ESA-naïve. 44% of patients without transfusion had a haemoglobin 
level within 10–12 g/dL around 6 months of treatment. For ESA-naïve patients, most 
patients with a haemoglobin level lower than 10 g/dL at 3 months remained below the 
target at 6 months. Regarding non ESA-naïve patients, most patients with a haemo-
globin level greater than 12 g/dL at 3 months remained above the target at 6 months. 
Dose adjustments were not performed for 2/3 of patients around 3 months when 
haemoglobin was outside the target range. cOnclusiOns: These techniques on real 
world data seems to be a way to broaden the pathology, compound and practice pat-
terns interactions. Dose adjustment around 3 months of treatment is a key factor for 
achieving the recommended haemoglobin target after 6 months. Our study confirms 
the importance of personalized anaemia management based on the patient’s profile.
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Objectives: This study aims to determine the patterns of medication use in 
patients with chronic kidney disease (CKD) stage 5D with special focus on drugs 
for the management of chronic kidney disease-mineral and bone disorder (CKD-
MBD). MethOds: A retrospective, observational study was conducted at Hospital 
Universiti Sains Malaysia. Medical records of 134 adult patients with CKD stage 5D 
were reviewed from January-April, 2014. Data regarding patient’s demographics, 
co-morbidities and medications were collected. The medications prescribed were 
classified according to the Anatomic Therapeutic Chemical classification recom-
mended by World Health Organization. The drugs were further categorized as clinic 
and home medications. Comparisons were made between age groups (≤ 50 or > 50 
years), gender and diabetic status. Results: Patients were 52.97 ± 14.05 years old, 
and were prescribed 12.88 ± 4.14 medications (10.00 ± 2.88 home medications and 
2.88 ± 2.99 clinic medications). Patient’s gender had no influence on the number of 
prescribed medications. However, patients with diabetes and elderly patients were 
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Objectives: To determine the prescribing pattern of specialized physicians for 
tuberculosis in Punjab, Pakistan. MethOds: A drug utilization study was conducted 
at community pharmacies among tuberculosis patients attending tertiary hospitals. 
A stratified sampling technique was used for selecting community pharmacies. 
Prescriptions written by tuberculosis specialized physicians were collected and 
analyzed according to WHO standard treatment guidelines. Results: The data 
were gathered from 750 prescriptions. Unfair number of drugs were prescribed 
in which the mean number of drugs in a single prescription was 7.0 (+2.1). The 
value of prescribing indicators was more than the WHO standard indicators. Most 
of the prescribed medicines (95%) were written in their brand names. Moreover, 
the frequently prescribed medicines were antibiotics (37.7%); anxiolytics (23.5%); 
and corticosteroids (29%). cOnclusiOns: Physicians’ adherence to the standard 
practicing guidelines was poor although the affordability of medicines was fair but 
still the prescribing pattern needs to be apposite. Implementation of administra-
tive strategies to improve the current prescribing pattern as well as patient-educa-
tional programs concerning the tuberculosis treatment are of utmost importance. 
In addition, further studies are required in other provinces of Pakistan in order to 
understand the complete prescribing behavior of the physician to treat tuberculosis 
throughout the country.
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Objectives: The aim of the study was to investigate 1) if the average Pakistanis and 
average Italian kidney post transplanted patients have same episodes of adverse 
events after intake of cyclosporine,tacrolimus and corticosteroids 2) and to green 
light the safest as well as hazardous drug among these three with appropriate rea-
sons for effectiveness and ineffectiveness. MethOds: The subjects were randomly 
selected including 706 pakistani and 568 italian patients both male and female with 
inclusion criteria of teen age and geriatric patients.Blood sample was taken from 
each subject in order to determine the amount of creatinine,glucose,hemoglobin 
and cholesterol.Urine sample was also taken in order to determine level of pro-
tein.Also Delayed Graft Function (DFG) was observed in these subjects. Results: 
Thirty one percent of Italian men and 26% of Italian women suffered from hyper-
creatininemia and hyperproteinuria including hemoglobinemia and hyper-
cholesterolemia whereas 22% of Pakistani men and 21.50% of Pakistani women 
experienced same adverse effects.It was observed that majority of adverse effects 
were found between age group 46-55 and found to be least between age group 
17-25. cOnclusiOns: It was concluded that for immuno-compromised patients 
DGF,mortality rate and risk of transplant failure has been shown minimum for 
corticosteroids,intermediate for tacrolimus and maximum for cyclosporine and 
for immuno-competent patients,tacrolimus was effective drug. As cyclosporine 
which is composed of 11-amino acids,is followed by a competitive receptor bind-
ing with proteins whose level exceeds the upper limit in abnormal kidney function 
and hence those amino acids having same ‘R’ functionality with attaching side 
of cyclosporine will compete leading to unavailability of cyclosporine.Also it was 
observed that patient’s adherence was maximum with corticosteroids as they pro-
duce synergistic effect with adrenal gland’s steroid production.These data suggest 
that immuno-suppressants should be monitored with special care depending upon 
the immune status of patient.
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Objectives: In order to determine the GFR different equations had been used, 
mainly CG, the MDRD and CKD-EPI; with differences in estimation of renal func-
tion by these equation, therefore we defined to determine the correlation between 
these to estimate GFR in patients with hypertension (HT), diabetes (DM) or some 
stage of chronic kidney disease (CKD). MethOds: Data from 3.055.568 patients 
over 18 years with HT, DM and CKD was used. Prediction limits for differences 
between pairs of measurements using the limits according to Bland and Altman 
were calculated and plotted, the valuesLin correlation coefficients between MDRD- 
CG, CG-CKD/EPI and CKD/EPI-MDRD couples, considering that the three methods 
provide results measurement in the same scale. Results: 1.348.214 patients were 
included, 832.129 women (61.7%). The age mean was 64.3 years (standard deviation 
(SD) 13.2), 50% of patients were between 60 and 74 years old. 94% had diagnosis of HT 
and 26% of DM. The intraclass correlation coefficient (ICC) between CG and DMRD 
was 0.704 with 95% of (0.703- 0.705) with a difference mean of 3.5 and Bland and 
Altman agreed limits from -31.65 to 43.83; ICC being CG and CKD-EPI is 0.728 with 
a CI 95% (0.729-0.730) with a difference mean of 1.73 and Bland and Altman agreed 
limits from -37.26 to 40.62 and correlation coefficient being intraclass CKD-EPI and 
MDRD is 0.855 with 95% of (0.855, 0.856) with a difference mean of -1.86 and Bland 
and Altman agreed limits from -25.61 and 21.89. cOnclusiOns: General popula-
tion studies have reported a good correlation comparison between DRMD and CKD 
-EPI, our results in CKD population and precursor disease, also have shown a good 
correlation between them. Similar findings have been observed in other reports. 
